Drug Type AAV based gene therapy |
Synonyms AAV-TB5-CX26 |
Target |
Mechanism GJB2 modulators(gap junction protein beta 2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hearing Loss | Preclinical | JP | 23 Apr 2024 |